Cytomx Therapeutics Inc 's ability to collect accounts receivable sequentially worsen to 1.75, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Cytomx Therapeutics Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 209 days, from 16 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 495 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2399 to 2964.

What is Receivable Turnover Ratio?
What is Cytomx Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CTMX Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	1906.1 %	-66.97 %	-35.13 %	-51.4 %	-32.65 %
Y / Y Revenue Change	-92.4 %	-79.85 %	-98.26 %	-82.16 %	-25.71 %
Receivable Turnover Ratio (TTM)	1.75	23.09	40.82	53.12	54.9
CTMX's Total Ranking	# 2964	# 2399	# 1752	# 246	# 704
Accounts Receivable average collection period days	208	16	9	7	7
Seq. Receivable Change	5704.02 %	-67.91 %	23.57 %	-12.84 %	-4.45 %
Seq. Revenue Change	-86.18 %	1447.21 %	-88.88 %	-68.04 %	-63.36 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 170
Healthcare Sector	# 496
Overall Market	# 2964

Receivable Turnover Ratio Statistics
High	Average	Low
1.14	0.3	0.05
(Mar 31 2025)		(Jun 30 2016)

CTMX Company Profile • Back to CTMX Efficiency Comparisons • Compare CTMX Receivables Turnover Ratio to its Competitors

Financial Statements
Cytomx Therapeutics Inc 's Accounts Receivable	$ 37 Millions	Visit CTMX's Balance sheet
Cytomx Therapeutics Inc 's Sales TTM	$ 18 Millions	Visit CTMX's Income Statement
Sources of CTMX's Revenues		Visit CTMX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
CTMX's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
CTMX's Growth Rates	CTMX's Roa	CTMX's Inventory Turnover Ratio	CTMX's Dividend Comparisons
CTMX's Profitability Ratios	CTMX's Roi	CTMX's Asset Turnover Ratio	CTMX's Dividend Growth
CTMX's Valuation Ratios	CTMX's Roe	CTMX's Financial Strength Ratios	CTMX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Regen Biopharma Inc	0.99	$ 0.237 Millions	$ 0.239 Millions
IMPACT BIOMEDICAL INC.	0.69	$ 0.035 Millions	$ 0.051 Millions
Cardiff Lexington Corporation	0.46	$ 10.213 Millions	$ 22.347 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.